cas 68166-83-6|| where to buy (R)-tert-Butyl 2-hydroxypropanoate

製品名:(R)-tert-Butyl 2-hydroxypropanoate

IUPAC Name:tert-butyl (2R)-2-hydroxypropanoate

包装単位	有効在庫	価格（USD）
CM166370-250mg	in stock	ȐȐ
CM166370-1g	in stock	ȯŪǫ
CM166370-5g	1-2 Weeks	ǫȯƿƃ

研究開発用専用.

問い合わせフォーム

化学物質名

CAS番号

数量*

要求仕様*
（アッセイ %、材料グレード等）

お名前*

連絡先Eメールアドレス*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 68166-83-6 regularly via the above email.

追記事項

Verification code*

refresh

: CAS番号:68166-83-6; 分子式:C7H14O3; 融点:-; SMILESコード:C[C@@H](O)C(OC(C)(C)C)=O; 密度:

: カタログ番号:CM166370; 分子量:146.19; 沸点:; MDL番号:MFCD00191884; 保管方法:

: Aliphatic Chain Compounds; Aliphatic chain compounds include aliphatic compounds and chain compounds containing other elements or groups. Aliphatic hydrocarbons are hydrocarbons with the basic properties of aliphatic compounds. In aliphatic compounds, carbon atoms are arranged in straight chain, branched chain or cyclic, which are respectively called straight chain aliphatic hydrocarbons, branched chain aliphatic hydrocarbons and alicyclic hydrocarbons. Some cyclic hydrocarbons are different in nature from aromatic hydrocarbons, and are very similar to aliphatic hydrocarbons. Such cyclic hydrocarbons are called alicyclic hydrocarbons. In this way, aliphatic hydrocarbons become a general term for all hydrocarbons except aromatic hydrocarbons. Aliphatic hydrocarbons and their derivatives (including halogenated hydrocarbons) and alicyclic hydrocarbons and their derivatives are collectively referred to as aliphatic compounds.

: NMD670; NMD Pharma A/S announces that it has dosed the first generalized myasthenia gravis patient in a Phase 2b clinical trial of NMD670, after receiving FDA IND clearance in March 2024 to conduct the study.
NMD670 is a first-in-class small molecule inhibitor of the skeletal muscle specific chloride ion channel (CIC-1). NMD Pharma has demonstrated that CIC-1 inhibition enhances weakened neuromuscular transmission and restores skeletal muscle function, and this novel treatment approach has demonstrated compelling preclinical and clinical data in animal models of myasthenia gravis, spinal muscular atrophy and a range of other neuromuscular disorders. NMD670 has also been granted orphan-drug designation by the U.S. FDA for treatment of gMG.